To further assess whether carboplatin can be de-escalated, the ongoing COMPASS HER2 trail is enrolling patients with stage II and III HER2-positive breast cancer being treated with THP neoadjuvant therapy [29]. Here, ERBB2 is linked to breast carcinoma.